German Registry Data Analysis of Degarelix (Firmagon®) for Prostate Cance
The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common [...]
Analyzing the Analysis – Is Surgery Superior to Radiotherapy? No, Despite the Results from A Large Canadian Study
It is a little out of the normal scope of this blog, but a recent prostate cancer study from Canada has received a lot of buzz and needs some commentary and analysis. The study concluded [...]
NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment
NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. [...]
Perhaps My Most Important Post
As we reach this holiday season I want to remind you that Malecare has been working to help you and your family survive longer and have a better quality of life. We have helped you in [...]
U.S. Congress Passes Omnibus Funding with Significant Increases for Medical Research
We have some good news, the United States Congress has passed the Omnibus spending package. The package will fund the U.S. Government through fiscal 2016. We should take note that this bill includes a $2 [...]
CMS Continues To Limit Coverage For NaF-18 PET Scans For Bone Metastases
There has been a lot of buzz around the new scanning contrasts that have come into limited usage for evaluating metastasized cancer cells that are in the bones. Despite the enthusiasm from the prostate and [...]